Amiodarone Prophylaxis for Atrial Fibrillation After Cardiac Surgery: Meta-Analysis of Dose Response and Timing of Initiation
Corresponding Author
Dr. Mitchell S. Buckley Pharm. D., BCPS
Department of Pharmacy, St. Joseph's Hospital and Medical Center, Phoenix, Arizona
Department of Pharmacy, St. Joseph's Hospital and Medical Center, 350 West Thomas Road, Phoenix, AZ 85013; e-mail: [email protected].Search for more papers by this authorDr. Paul E. Nolan Jr. Pharm. D.
Department of Pharmacy Practice and Science, College of Pharmacy
Search for more papers by this authorMarion K. Slack Ph. D.
Department of Pharmacy Practice and Science, College of Pharmacy
Search for more papers by this authorJames E. Tisdale Pharm. D.
Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Purdue University
School of Medicine, Indiana University, Indianapolis, Indiana
Search for more papers by this authorDr. Daniel E. Hilleman Pharm. D.
Creighton University Cardiac Center, Omaha, Nebraska.
Search for more papers by this authorJack G. Copeland M. D.
Sarver Heart Center, University of Arizona, Tucson, Arizona
Search for more papers by this authorCorresponding Author
Dr. Mitchell S. Buckley Pharm. D., BCPS
Department of Pharmacy, St. Joseph's Hospital and Medical Center, Phoenix, Arizona
Department of Pharmacy, St. Joseph's Hospital and Medical Center, 350 West Thomas Road, Phoenix, AZ 85013; e-mail: [email protected].Search for more papers by this authorDr. Paul E. Nolan Jr. Pharm. D.
Department of Pharmacy Practice and Science, College of Pharmacy
Search for more papers by this authorMarion K. Slack Ph. D.
Department of Pharmacy Practice and Science, College of Pharmacy
Search for more papers by this authorJames E. Tisdale Pharm. D.
Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Purdue University
School of Medicine, Indiana University, Indianapolis, Indiana
Search for more papers by this authorDr. Daniel E. Hilleman Pharm. D.
Creighton University Cardiac Center, Omaha, Nebraska.
Search for more papers by this authorJack G. Copeland M. D.
Sarver Heart Center, University of Arizona, Tucson, Arizona
Search for more papers by this authorAbstract
Study Objective. To investigate a possible dose-response relationship between amiodarone and reduction in incidence of postoperative atrial fibrillation, and to determine whether pre- or postoperative initiation of amiodarone is superior.
Design. Meta-analysis of randomized controlled trials.
Data Source. MEDLINE and EMBASE databases and the Cochrane Central Register of Controlled Trials for English-language reports published between 1966 and December 2005.
Measurements and Main Results. Of 23 identified randomized controlled trials of amiodarone prophylaxis of postoperative atrial fibrillation, 14 were included in the final analysis. These studies enrolled a total of 2864 patients. For each study, the total administered amiodarone dose—categorized as low (< 3000 mg), medium (3000–5000 mg), or high (> 5000 mg)—and preoperative versus postoperative initiation were aggregated by using meta-analytic techniques. The incidence of postoperative atrial fibrillation was significantly reduced by amiodarone compared with placebo (p<0.001). Although the odds of developing atrial fibrillation appeared to be somewhat higher in the low-dose group, no significant differences were noted in the odds ratios (ORs) of developing atrial fibrillation among the low-, medium-, and high-dose groups: OR 0.58, 95% confidence interval (CI) 0.44–0.77; OR 0.45, 95% CI 0.30–0.69; and OR 0.44, 95% CI 0.33–0.58; respectively (p=0.238). In addition, the ORs for atrial fibrillation development associated with preoperative and postoperative initiation of amiodarone were not significantly different (OR 0.50, 95% CI 0.39–0.63; and OR 0.48, 95% CI 0.37–0.63; respectively, p=0.862).
Conclusion. Total amiodarone doses of 3000 mg or higher may be more effective than lower doses in reducing the rate of postoperative atrial fibrillation after cardiac surgery. Preoperative initiation of amiodarone appears to be unnecessary. These findings require confirmation in prospective, randomized trials.
References
- 1 Maisel WH, Rawn JD, Stevenson WG. Atrial fibrillation after coronary surgery. Ann Intern Med 2001; 135: 1061–73.
- 2 Villareal RP, Hariharan R, Liu BC, et al. Postoperative atrial fibrillation and mortality after coronary artery bypass surgery. J Am Coll Cardiol 2004; 43: 742–8.
- 3 Ommen SR, Odell JA, Stanton MS. Atrial fibrillation after cardiothoracic surgery. N Engl J Med 1997; 336: 1429–34.
- 4 Almassi GH, Schowalter R, Nicolosi AC, et al. Atrial fibrillation after cardiac surgery: a major morbid event? Ann Surg 1997; 226: 501–13.
- 5 Aranki SF, Shaw DP, Adams DH, et al. Predictors of atrial fibrillation after coronary artery surgery: current trends and impact on hospital resources. Circulation 1996; 94: 390–7.
- 6 Bradley D, Creswell LL, Hogue CW Jr, et al. Pharmacologic prophylaxis: American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery. Chest 2005; 128(suppl 2): S39–47.
- 7 Davison R, Hartz R, Kaplan K, Parker M, Feiereisel P, Michaelis L. Prophylaxis of supraventricular tachyarrhythmia after coronary bypass surgery with oral verapamil: a randomized, double-blind trial. Ann Thorac Surg 1985; 39: 336–9.
- 8 Mills SA, Poole GV, Breyer RH, et al. Digoxin and propranolol in the prophylaxis of dysrhythmias after coronary artery bypass grafting. Circulation 1983; 68(3 pt 2): II222–5.
- 9 Roffman JA, Fieldman A. Digoxin and propranolol in the prophylaxis of supraventricular tachydysrhythmias after coronary artery bypass surgery. Ann Thorac Surg 1981; 31: 496–501.
- 10 Williams DB, Misbach GA, Kruse AP, Ivey TD. Oral verapamil for prophylaxis of supraventricular tachycardia after myocardial revascularization. J Thorac Cardiovasc Surg 1985; 90: 592–6.
- 11 Butler J, Harriss DR, Sinclair M, et al. Amiodarone prophylaxis for tachycardias after coronary artery surgery: a randomized, double blind, placebo controlled trial. Br Heart J 1993; 70: 56–60.
- 12 Daoud EG, Strickberger SA, Man KC, et al. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. N Engl J Med 1997; 337: 1785–91.
- 13 Dörge H, Schoendube FA, Schoberer M, et al. Intraoperative amiodarone as prophylaxis against atrial fibrillation after coronary operations. Ann Thorac Surg 2000; 69: 1358–62.
- 14 Giri S, White CM, Dunn AB, et al. Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the atrial fibrillation suppression trial (AFIST): a randomised placebo-controlled trial. Lancet 2001; 357: 830–6.
- 15 Guarnieri T, Nolan S, Gottlieb SO, et al. Intravenous amiodarone for the prevention of atrial fibrillation after open heart surgery: the amiodarone reduction in coronary heart (ARCH) trial. J Am Coll Cardiol 1999; 34: 343–7.
- 16 Harahsheh BS, Sawalha WA. Effect of amiodarone on atrial fibrillation after coronary artery bypass surgery. Saudi Med J 2001; 22: 797–9.
- 17 Hohnloser SH, Meinertz T, Dammbacher T, et al. Electrocardiographic and antiarrhythmic effects of intravenous amiodarone: results of a prospective, placebo-controlled study. Am Heart J 1991; 121: 89–95.
- 18 Katariya K, DeMarchena E, Bolooki H, et al. Oral amiodarone reduces incidence of postoperative atrial fibrillation. Ann Thorac Surg 1999; 68: 1599–604.
- 19 Kerstein J, Soodan A, Qamar M, et al. Giving IV and oral amiodarone perioperatively for the prevention of postoperative atrial fibrillation in patients undergoing coronary artery bypass surgery: the GAP study. Chest 2004; 126: 716–24.
- 20 Kuralay E, Cingöz F, Kilic S, et al. Supraventricular tachyarrhythmia prophylaxis after coronary artery surgery in chronic obstructive pulmonary disease patients (early amiodarone prophylaxis trial). Eur J Cardiothorac Surg 2004; 25: 224–30.
- 21 Lee SH, Chang CM, Lu MJ, et al. Intravenous amiodarone for prevention of atrial fibrillation after coronary artery bypass grafting. Ann Thorac Surg 2000; 70: 157–61.
- 22 Maras D, Boskovic SD, Popovic Z, et al. Single-day loading dose of oral amiodarone for the prevention of new-onset atrial fibrillation after coronary artery bypass surgery. Am Heart J 2001; 141: e8–15.
- 23 Mikroulis D, Didilis V, Konstantinou F, et al. Diltiazem versus amiodarone to prevent atrial fibrillation in coronary surgery. Asian Cardiovasc Thorac Ann 2005; 13: 47–52.
- 24 Mitchell LB, Exner DV, Wyse DG, et al. Prophylactic oral amiodarone for the prevention of arrhythmias that begin early after revascularization, valve replacement, or repair (PAPABEAR): a randomized controlled trial. JAMA 2005; 294: 3093–100.
- 25 Mooss AN, Wurdeman RL, Sugimoto JT, et al. Amiodarone versus sotalol for the treatment of atrial fibrillation after open heart surgery: the reduction in postoperative cardiovascular arrhythmic events (REDUCE) trial. Am Heart J 2004; 148: 641–8.
- 26 Redle JD, Khurana S, Marzan R, et al. Prophylactic oral amiodarone compared with placebo for prevention of atrial fibrillation after coronary artery bypass surgery. Am Heart J 1999; 138: 144–50.
- 27 Solomon AJ, Greenberg MD, Kilborn MJ, et al. Amiodarone versus a β-blocker to prevent atrial fibrillation after cardiovascular surgery. Am Heart J 2001; 142: 811–15.
- 28 Stamou SC, Hill PC, Sample GA, et al. Prevention of atrial fibrillation after cardiac surgery: the significance of postoperative oral amiodarone. Chest 2001; 120: 1936–41.
- 29 Tokmakoglu H, Kandemir O, Gunaydin S, et al. Amiodarone versus digoxin and metoprolol combination for the prevention of postcoronary bypass atrial fibrillation. Eur J Cardiothorac Surg 2002; 21: 401–5.
- 30 Treggiari-Venzi MM, Waeber JL, Perneger TV, et al. Intravenous amiodarone or magnesium sulphate is not cost-beneficial prophylaxis for atrial fibrillation after coronary artery bypass surgery. Br J Anaesth 2000; 85: 690–5.
- 31 White CM, Caron MF, Kalus JS, et al. Intravenous plus oral amiodarone, atrial septal pacing, or both strategies to prevent post-cardiothoracic surgery atrial fibrillation: the atrial fibrillation suppression trial II (AFIST II). Circulation 2003; 108(suppl 1): II200–6.
- 32 Yagdi T, Nalbantgil S, Ayik F, et al. Amiodarone reduces the incidence of atrial fibrillation after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2003; 125: 1420–5.
- 33 Yazigi A, Rahbani P, Zeid HA, et al. Postoperative oral amiodarone as prophylaxis against atrial fibrillation after coronary artery surgery. J Cardiothorac Vasc Anesth 2002; 16: 603–6.
- 34 Abel RM, van Gelder HM, Pores IH, Liguori J, Gielchinsky I, Parsonnet V. Continued propranolol administration following coronary bypass surgery: antiarrhythmic effects. Arch Surg 1983; 118: 727–31.
- 35 Coleman CI, Perkeson KA, Gillespie EL, et al. Impact of prophylactic postoperative β-blockade on post-cardiothoracic surgery length of stay and atrial fibrillation. Ann Pharmacother 2004; 38: 2012–16.
- 36 Connolly SJ, Cybulsky I, Lamy A, et al. Double-blind, placebo-controlled, randomized trial of prophylactic metoprolol for reduction of hospital length of stay after heart surgery: the β-blocker length of stay (BLOS) study. Am Heart J 2003; 145: 226–32.
- 37 Daudon P, Corcos T, Gandjbakhch I, Lavasseur J, Cabrol A, Cabrol C. Prevention of atrial fibrillation by acebutolol after coronary bypass grafting. Am J Cardiol 1986; 58: 933–6.
- 38 Ivey MF, Ivey TD, Baily WW, Williams DB, Hessel EA, Miller DW. Influence of propranolol on supraventricular tachycardia early after coronary artery revascularization: a randomized trial. J Thorac Cardiovasc Surg 1983; 85: 214–18.
- 39 Khuri SF, Okike N, Josa M, et al. Efficacy of nadolol in preventing supraventricular tachycardia after coronary artery bypass grafting. Am J Cardiol 1987; 60: D51–8.
- 40 Lamb RK, Prabhakar G, Thorpe JAC, Smith S, Norton R, Dyde JA. The use of atenolol in the prevention of supraventricular arrhythmias following coronary artery surgery. Eur Heart J 1988; 9: 32–6.
- 41 Merritt JC, Neibauer M, Tarakji K, Hammer D, Mills RM. Comparison of effectiveness of carvedilol versus metoprolol or atenolol for atrial fibrillation appearing after coronary artery bypass grafting or cardiac valve operation. Am J Cardiol 2003; 92: 735–6.
- 42 Silverman NA, Wright R, Levitsky S. Efficacy of low-dose propranolol in preventing postoperative supraventricular tachyarrhythmias: a prospective, randomized study. Ann Surg 1982; 196: 194–7.
- 43 White HD, Antman EM, Glynn MA, et al. Efficacy and safety of timolol for prevention of supraventricular tachyarrhythmias after coronary artery bypass surgery. Circulation 1984; 70: 479–84.
- 44 Gomes JA, Ip J, Santoni-Rugiu F, et al. Oral d, l sotalol reduces the incidence of postoperative atrial fibrillation in coronary artery bypass surgery patients: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1999; 34: 334–9.
- 45 Suttorp MJ, Kingma JH, Peels HO, et al. Effectiveness of sotalol in preventing supraventricular tachyarrhythmias shortly after coronary artery bypass grafting. Am J Cardiol 1991; 68: 1163–9.
- 46 Suttorp MJ, Kingma JH, Gin Tjon Joe RM, et al. Efficacy and safety of low- and high-dose sotalol versus propranolol in the prevention of supraventricular tachyarrhythmias early after coronary artery bypass operations. J Thorac Cardiovasc Surg 1990; 100: 921–6.
- 47 Sanjuán R, Blasco M, Carbonell N, et al. Preoperative use of sotalol versus atenolol for atrial fibrillation after cardiac surgery. Ann Thorac Surg 2004; 77: 838–43.
- 48 Parikka H, Toivonen L, Heikkilä L, Virtanen K, Järvinen A. Comparison of sotalol and metoprolol in the prevention of atrial fibrillation after coronary artery bypass surgery. J Cardiovasc Pharmacol 1998; 31: 67–73.
- 49 Aasbo JD, Lawrence AT, Krishnan K, et al. Amiodarone prophylaxis reduces major cardiovascular morbidity and length of stay after cardiac surgery: a meta-analysis. Ann Intern Med 2005; 143: 327–36.
- 50 Crystal E, Connolly SJ, Sleik K, et al. Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. Circulation 2002; 106: 75–80.
- 51 Gillespie EL, Coleman CI, Sander S, et al. Effect of prophylactic amiodarone on clinical and economic outcomes after cardiothoracic surgery: a meta-analysis. Ann Pharmacother 2005; 39: 1409–15.
- 52 Wurdeman RL, Mooss AN, Mohiuddin SM, et al. Amiodarone vs sotalol as prophylaxis against atrial fibrillation/atrial flutter after heart surgery: a meta-analysis. Chest 2002; 121: 1203–10.
- 53 Mokdad AH, Serdula MK, Dietz WH, et al. The spread of the obesity epidemic in the United States, 1991–1998. JAMA 1999; 282: 1519–22.
- 54 Goldschlager N, Epstein AE, Naccarelli G, et al. Practical guidelines for clinicians who treat patients with amiodarone. Practice guidelines subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med 2000; 160: 1741–8.
- 55 Anastasiou-Nana M, Levis GM, Moulopoulos S. Pharmacokinetics of amiodarone after intravenous and oral administration. Int J Clin Pharmacol Ther Toxicol 1982; 20: 524–9.
- 56 Andreasen F, Agerbaek H, Bjerregaard P, et al. Pharmacokinetics of amiodarone after intravenous and oral administration. Eur J Clin Pharmacol 1981; 19: 293–9.
- 57 Holt DW, Tucker GT, Jackson PR, et al. Amiodarone pharmacokinetics. Am Heart J 1983; 106: 840–7.
- 58 Pourbaix S, Berger Y, Desager J, et al. Absolute bioavailability of amiodarone in normal subjects. Clin Pharmacol Ther 1985; 37: 118–23.
- 59 Riva E, Gerna M, Latini R, et al. Pharmacokinetics of amiodarone in men. J Cardiovasc Pharmacol 1982; 4: 264–9.
- 60
Egger M,
Smith GD,
Altman DG.
Systematic reviews in health care: meta-analysis in context. London, United Kingdom: BMJ Publishing Group, 2001.
10.1002/9780470693926 Google Scholar